Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Clinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Education and early detection of any type of dementia is important and may provide an opportunity for changing the course of ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...